Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy

Evaluation of Aficamten in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Withdrawal of Background Standard of Care Medical Therapy in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in REDWOOD HCM OLE

Effects of Omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial

Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Influence of Atrial Fibrillation on Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure: the GALACTIC-HF Trial

Adverse Drug Effects Across Patients With Heart Failure: A Systematic Review

Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF

Managing the Economic Challenges in the Treatment of Heart Failure